BioPharmSignal logoBioPharmSignal

Biotech News

Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results

Lucid Diagnostics (LUCD)Lucid DiagnosticsEarnings

LUCD (LUCD) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is lucd.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

LUCDLucid Diagnostics2026-07-30 12:30 EST

Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026

DGXQuest Diagnostics2026-07-23 10:45 EST

Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026

BMEABiomea Fusion2026-08-05 20:05 EST

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

ZNTLZentalis2026-08-06 20:05 EST

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

IMCRImmunocore Holdings plc2026-08-06 11:00 EST

Immunocore reports second quarter financial results and provides a business update

CHRSCoherus BioSciences, Inc.2026-08-05 20:28 EST

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

EXELExelixis2026-08-05 20:05 EST

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update

ELVNEnliven Therapeutics2026-08-05 20:05 EST

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

View all latest news

Lucid Diagnostics

Esophageal Cancer Prevention Company Lucid Diagnostics is a commercial-stage diagnostics subsidiary of PAVmed focused on detecting esophageal precancer in patients with chronic gastroesophageal reflux disease. EsoGuard and EsoCheck The EsoGuard DNA test is performed on samples collected with the non-endoscopic EsoCheck cell-collection...

Recent company news

LUCDLucid Diagnostics2026-08-05 12:46 EST

Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test

LUCDLucid Diagnostics2026-08-04 12:30 EST

Lucid Diagnostics to Participate in Upcoming Investor Conferences

LUCDLucid Diagnostics2026-07-30 12:30 EST

Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026

LUCDLucid Diagnostics2026-05-14 12:00 EST

Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results

LUCDLucid Diagnostics2026-04-30 12:31 EST

Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026

Stock data

Close
0.95 USD
Market cap
196.48M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States